{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:47:53Z","timestamp":1790232473864,"version":"4.1.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Novel combination therapies have markedly improved the lifespan of patients with multiple myeloma (MM), but drug resistance and disease relapse remain major clinical problems. Dexamethasone and other glucocorticoids are a cornerstone of conventional and new combination therapies for MM, although their use is accompanied by serious side effects. We aimed to uncover drug combinations that act in synergy and, as such, allow reduced dosing while remaining effective. Dexamethasone and the myeloid cell leukemia 1 (MCL-1) inhibitor S63845 (MCL-1i) proved the most potent combination in our lethality screen and induced apoptosis of human myeloma cell lines (HMCLs) that was 50% higher compared with an additive drug effect. Kinome analysis of dexamethasone-treated HMCLs revealed a reduction in serine\/threonine peptide phosphorylation, which was predicted to result from reduced Akt activity. Biochemical techniques showed no dexamethasone-induced effects on FOXO protein or GSK3 but did show a 50% reduction in P70S6K phosphorylation, downstream of the Akt-mTORC1 axis. Replacing dexamethasone by the P70S6K1 isoform-specific inhibitor PF-4708671 (S6K1i) revealed similar and statistically significant synergistic apoptosis of HMCLs in combination with MCL-1i. Interestingly, apoptosis induced by the P70S6K1i and MCL-1i combination was more-than-additive in all 9 primary MM samples tested; this effect was observed for 6 of 9 samples with the dexamethasone and MCL-1i combination. Toxicity on stem and progenitor cell subsets remained minimal. Combined, our results show a strong rationale for combination treatments using the P70S6K inhibitor in MM. Direct and specific inhibition of P70S6K may also provide a solution for patients ineligible or insensitive to dexamethasone or other glucocorticoids.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003624","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T11:32:10Z","timestamp":1624275130000},"page":"2593-2607","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma"],"prefix":"10.1182","volume":"5","author":[{"given":"Ingrid","family":"Spaan","sequence":"first","affiliation":[{"name":"Center for Translational Immunology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Timmerman","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kimman","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Slomp","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cuenca","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"van Nieuwenhuijzen","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology and"},{"name":"Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Moesbergen","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier A.","family":"Raymakers","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Peperzak","sequence":"additional","affiliation":[{"name":"Center for Translational Immunology and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"issue":"1","key":"2021062115315090200_B1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J Hematol Oncol."},{"key":"2021062115315090200_B2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fonc.2018.00533","article-title":"Role and regulation of pro-survival BCL-2 proteins in multiple myeloma","volume":"8","author":"Slomp","year":"2018","journal-title":"Front Oncol."},{"issue":"2","key":"2021062115315090200_B3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat Rev Cancer."},{"issue":"7","key":"2021062115315090200_B4","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","article-title":"Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival","volume":"19","author":"Wuill\u00e8me-Toumi","year":"2005","journal-title":"Leukemia."},{"issue":"1","key":"2021062115315090200_B5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs."},{"issue":"7626","key":"2021062115315090200_B6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature."},{"issue":"12","key":"2021062115315090200_B7","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov."},{"issue":"7","key":"2021062115315090200_B8","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/s41418-020-0498-z","article-title":"Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells","volume":"27","author":"Teh","year":"2020","journal-title":"Cell Death Differ."},{"issue":"2","key":"2021062115315090200_B9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-020-0273-x","article-title":"Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J."},{"issue":"11","key":"2021062115315090200_B10","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.3109\/10428194.2010.506570","article-title":"Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations","volume":"51","author":"Kfir-Erenfeld","year":"2010","journal-title":"Leuk Lymphoma."},{"issue":"6","key":"2021062115315090200_B11","first-page":"1681","article-title":"Mechanisms of glucocorticoid-mediated apoptosis in hematological malignancies","volume":"8","author":"Greenstein","year":"2002","journal-title":"Clin Cancer Res."},{"issue":"27","key":"2021062115315090200_B12","doi-asserted-by":"crossref","first-page":"24453","DOI":"10.1074\/jbc.C100074200","article-title":"Apaf-1\/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells","volume":"276","author":"Chauhan","year":"2001","journal-title":"J Biol Chem."},{"issue":"3","key":"2021062115315090200_B13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol."},{"issue":"19","key":"2021062115315090200_B14","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2015-05-612960","article-title":"How I treat fragile myeloma patients","volume":"126","author":"Larocca","year":"2015","journal-title":"Blood."},{"issue":"1","key":"2021062115315090200_B15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","article-title":"Glucocorticoids in multiple myeloma: past, present, and future","volume":"98","author":"Burwick","year":"2019","journal-title":"Ann Hematol."},{"issue":"13","key":"2021062115315090200_B16","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1182\/blood-2009-10-163329","article-title":"How I treat elderly patients with myeloma","volume":"116","author":"Mehta","year":"2010","journal-title":"Blood."},{"issue":"2","key":"2021062115315090200_B17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","article-title":"The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism","volume":"20","author":"Hoxhaj","year":"2020","journal-title":"Nat Rev Cancer."},{"issue":"9","key":"2021062115315090200_B18","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.onc.1205194","article-title":"Role of the AKT kinase in expansion of multiple myeloma clones: effects on cytokine-dependent proliferative and survival responses","volume":"21","author":"Hsu","year":"2002","journal-title":"Oncogene."},{"issue":"3","key":"2021062115315090200_B19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell."},{"issue":"11","key":"2021062115315090200_B20","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/13543784.2019.1676726","article-title":"Targeting AKT for cancer therapy","volume":"28","author":"Shariati","year":"2019","journal-title":"Expert Opin Investig Drugs."},{"issue":"4","key":"2021062115315090200_B21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1089\/ars.2010.3419","article-title":"The extending network of FOXO transcriptional target genes","volume":"14","author":"van der Vos","year":"2011","journal-title":"Antioxid Redox Signal."},{"issue":"6","key":"2021062115315090200_B22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.molcel.2006.02.009","article-title":"Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1","volume":"21","author":"Maurer","year":"2006","journal-title":"Mol Cell."},{"issue":"1","key":"2021062115315090200_B23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"1","key":"2021062115315090200_B24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20110892","article-title":"Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks","volume":"441","author":"Magnuson","year":"2012","journal-title":"Biochem J."},{"issue":"1","key":"2021062115315090200_B25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/PPO.0000000000000355","article-title":"Novel agents in multiple myeloma","volume":"25","author":"Szalat","year":"2019","journal-title":"Cancer J."},{"issue":"24","key":"2021062115315090200_B26","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/bloodadvances.2019000702","article-title":"Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting","volume":"3","author":"Slomp","year":"2019","journal-title":"Blood Adv."},{"issue":"11","key":"2021062115315090200_B27","doi-asserted-by":"crossref","first-page":"e1023973","DOI":"10.1080\/2162402X.2015.1023973","article-title":"Generation of a cord blood-derived Wilms tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation","volume":"4","author":"de Haar","year":"2015","journal-title":"OncoImmunology."},{"issue":"6","key":"2021062115315090200_B28","doi-asserted-by":"crossref","first-page":"e1434465","DOI":"10.1080\/2162402X.2018.1434465","article-title":"Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche model","volume":"7","author":"Braham","year":"2018","journal-title":"OncoImmunology."},{"issue":"2","key":"2021062115315090200_B29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3324\/haematol.2014.117531","article-title":"Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide","volume":"100","author":"Nijhof","year":"2015","journal-title":"Haematologica."},{"issue":"2","key":"2021062115315090200_B30","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"18","key":"2021062115315090200_B31","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s40265-017-0838-6","article-title":"Copanlisib: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs."},{"issue":"2","key":"2021062115315090200_B32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1042\/BJ20101024","article-title":"Characterization of PF-4708671, a novel and highly specific inhibitor of p70 ribosomal S6 kinase (S6K1)","volume":"431","author":"Pearce","year":"2010","journal-title":"Biochem J."},{"issue":"3","key":"2021062115315090200_B33","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res."},{"issue":"2","key":"2021062115315090200_B34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.bbamcr.2009.11.004","article-title":"Bim is the key mediator of glucocorticoid-induced apoptosis and of its potentiation by rapamycin in human myeloma cells","volume":"1803","author":"L\u00f3pez-Royuela","year":"2010","journal-title":"Biochim Biophys Acta."},{"issue":"5","key":"2021062115315090200_B35","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/leu.2015.350","article-title":"Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax","volume":"30","author":"Matulis","year":"2016","journal-title":"Leukemia."},{"issue":"17","key":"2021062115315090200_B36","doi-asserted-by":"crossref","first-page":"9666","DOI":"10.1073\/pnas.171301998","article-title":"p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD","volume":"98","author":"Harada","year":"2001","journal-title":"Proc Natl Acad Sci USA."},{"issue":"9","key":"2021062115315090200_B37","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/sj.onc.1205205","article-title":"Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays","volume":"21","author":"Chauhan","year":"2002","journal-title":"Oncogene."},{"issue":"6","key":"2021062115315090200_B38","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41419-020-2599-5","article-title":"Glucocorticoids can induce BIM to trigger apoptosis in the absence of BAX and BAK1","volume":"11","author":"Dong","year":"2020","journal-title":"Cell Death Dis."},{"issue":"26","key":"2021062115315090200_B39","doi-asserted-by":"crossref","first-page":"23861","DOI":"10.1074\/jbc.M301843200","article-title":"Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis","volume":"278","author":"Wang","year":"2003","journal-title":"J Biol Chem."},{"key":"2021062115315090200_B40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fendo.2017.00016","article-title":"New insights in glucocorticoid receptor signaling\u2014more than just a ligand-binding receptor","volume":"8","author":"Scheschowitsch","year":"2017","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"19","key":"2021062115315090200_B41","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0960-9822(00)00728-4","article-title":"Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1","volume":"10","author":"Dijkers","year":"2000","journal-title":"Curr Biol."},{"issue":"6","key":"2021062115315090200_B42","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1210\/me.2009-0466","article-title":"Glycogen synthase kinase-3 plays a central role in mediating glucocorticoid-induced apoptosis","volume":"24","author":"Spokoini","year":"2010","journal-title":"Mol Endocrinol."},{"issue":"10","key":"2021062115315090200_B43","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1158\/0008-5472.CAN-06-1788","article-title":"Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer","volume":"67","author":"Ding","year":"2007","journal-title":"Cancer Res."},{"issue":"2","key":"2021062115315090200_B44","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/leu.2012.180","article-title":"Downregulation of Mcl-1 through GSK-3\u03b2 activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia."},{"issue":"11","key":"2021062115315090200_B45","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1080\/10428194.2017.1421760","article-title":"PI3K\/AKT\/mTOR pathway in multiple myeloma: from basic biology to clinical promise","volume":"59","author":"Ramakrishnan","year":"2018","journal-title":"Leuk Lymphoma."},{"issue":"4","key":"2021062115315090200_B46","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4161\/cc.8.4.7659","article-title":"Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy","volume":"8","author":"Choo","year":"2009","journal-title":"Cell Cycle."},{"issue":"17","key":"2021062115315090200_B47","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1038\/emboj.2010.166","article-title":"S6K1 is a multifaceted regulator of Mdm2 that connects nutrient status and DNA damage response","volume":"29","author":"Lai","year":"2010","journal-title":"EMBO J."},{"issue":"2","key":"2021062115315090200_B48","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.molcel.2006.09.019","article-title":"S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt","volume":"24","author":"Zhang","year":"2006","journal-title":"Mol Cell."},{"key":"2021062115315090200_B49","first-page":"647","article-title":"Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies","volume":"2","author":"Scheijen","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"2021062115315090200_B50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-1-4939-2895-8_14","article-title":"Glucocorticoids and cancer","volume":"872","author":"Pufall","year":"2015","journal-title":"Adv Exp Med Biol."},{"issue":"1","key":"2021062115315090200_B51","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol Ther."},{"issue":"5","key":"2021062115315090200_B52","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ejca.2013.12.006","article-title":"A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours","volume":"50","author":"Hollebecque","year":"2014","journal-title":"Eur J Cancer."},{"issue":"5","key":"2021062115315090200_B53","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ejca.2013.11.039","article-title":"A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours","volume":"50","author":"Tolcher","year":"2014","journal-title":"Eur J Cancer."},{"issue":"1","key":"2021062115315090200_B54","doi-asserted-by":"crossref","first-page":"e0147185","DOI":"10.1371\/journal.pone.0147185","article-title":"The p70S6K specific inhibitor PF-4708671 impedes non-small cell lung cancer growth","volume":"11","author":"Qiu","year":"2016","journal-title":"PLoS One."},{"issue":"3","key":"2021062115315090200_B55","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.molonc.2014.02.006","article-title":"p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation","volume":"8","author":"Segatto","year":"2014","journal-title":"Mol Oncol."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/12\/2593\/1810381\/advancesadv2020003624.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/12\/2593\/1810381\/advancesadv2020003624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T19:42:31Z","timestamp":1672515751000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/12\/2593\/476188\/Direct-P70S6K1-inhibition-to-replace-dexamethasone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,6,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003624","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]}}}